Related Experiment Video
Updated: Jun 4, 2025
07:02
Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
Published on: May 11, 2018
13.3K
Evaluation of Spliceosome Protein SmD2 as a Potential Target for Cancer Therapy
Jing Li1,2, Peiyu Li1,2, Tereza Brachtlova1,2,3,4
1Amsterdam UMC location Vrije Universiteit Amsterdam, Medical Oncology, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
International Journal of Molecular Sciences
|December 17, 2024
Summary
SmD2, a core spliceosome protein, is overexpressed in most cancers and essential for cancer cell survival. Targeting SmD2 presents a promising cancer treatment strategy, revealing its non-canonical functions beyond mRNA splicing.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Core spliceosome Sm proteins are emerging as potential cancer therapeutic targets.
- SmD2, a key component of the spliceosome, is investigated for its role in cancer.
Purpose of the Study:
- To evaluate SmD2 as a cancer-selective lethal target.
- To investigate the functional consequences of SmD2 loss in cancer cells.
Main Methods:
- Pan-cancer analysis of SNRPD2 gene expression across 26 solid tumor types.
- SNRPD2 silencing using lentiviral vectors in various cancer and normal cell lines.
- Analysis of publicly available cell viability datasets for SmD2 dependency.
- Comparative analysis of gene essentiality profiles.
Main Results:
- SNRPD2 was overexpressed in nearly all analyzed cancers, correlating with poor prognosis in several.
- SmD2 loss was synthetically lethal in cancer cell lines but not normal cells.
- Loss of SmD2 intersected with defects in mRNA processing, protein production, and mitosis.
- SNRPD2 expression correlated with sensitivity to cell cycle-inhibiting anti-cancer drugs.
Conclusions:
- SmD2 is a validated cancer-selective lethal target.
- SmD2 plays crucial roles beyond mRNA splicing, contributing to cancer cell dependency.
- Targeting SmD2 holds significant therapeutic potential for cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:32RNA Splicing
56.0K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
56.0K